Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Email me when HR 8857 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 8857. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The Next GEN Act amends the Social Security Act to lengthen the market exclusivity for engineered cyclic peptide medicines from seven to eleven years when they are considered single‑source drugs under the Medicare drug price negotiation program. It also provides a specific definition of “engineered cyclic peptide.” The change aims to give developers more time to recoup investment while still allowing Medicare to negotiate prices for other drugs.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 8857
3 free questions a day, no accountSponsors
- Rep. Morelle, Joseph D. [D-NY-25] (D) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 8857 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 8857 freeOr ask your AI assistant about HR 8857 directly:
Add to Claude, ChatGPT or Cursor